Literature DB >> 19260109

Detection of CpG island hypermethylation of caspase-8 in neuroblastoma using an oligonucleotide array.

Arata Kamimatsuse1, Kaoru Matsuura, Shogo Moriya, Ikuko Fukuba, Hiroaki Yamaoka, Emi Fukuda, Naomi Kamei, Keiko Hiyama, Taijiro Sueda, Eiso Hiyama.   

Abstract

BACKGROUND: The caspase-8 gene (CASP8) is frequently inactivated in unfavorable neuroblastomas through DNA methylation. The present study utilized oligoarrays to evaluate the methylation status of a CpG island located between exons 2 and 3 of caspase 8 in neuroblastomas. PROCEDURE: DNA derived from 70 neuroblastomas was amplified by PCR after bisulfate modification and subjected to analysis on a self-made oligoarray that utilized a polycarbodiimide-coated slide to detect methylation of six intragenic CpG islands of caspase 8. In 30 cases, the methylation status was also analyzed by sequencing. In six cases, the PCR product was cloned into a vector and analyzed.
RESULTS: Among the 70 tumor-derived DNAs, methylation was not detected in 18 cases, one methylated CpG was found in 12 cases, two in 18 cases, three in 3 cases, four in 8 cases, five in 1 case and six in 10 cases. All methylated CpG loci detected by sequencing were detected by oligoarray, but some methylated CpGs in three loci were detected by oligoarray alone. In these discrepant loci, methylation was detected in some clones after subcloning, indicating that the oligoarray might be more sensitive than sequencing. The CASP8 expression level was depressed in the tumors having two distinct CpG doublets. These results were significantly correlated with MYCN amplification and with clinical outcomes.
CONCLUSIONS: A significant difference in the methylation status within the CpG island of CASP8 was shown between favorable and unfavorable subtypes, and CASP8 methylation detected by oligoarray may be useful in the clinical evaluation of neuroblastomas. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19260109     DOI: 10.1002/pbc.21977

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  4 in total

1.  Harnessing the cell death pathway for targeted cancer treatment.

Authors:  Christina K Speirs; Misun Hwang; Sungjune Kim; Weier Li; Sophia Chang; Vinod Varki; Lauren Mitchell; Stephen Schleicher; Bo Lu
Journal:  Am J Cancer Res       Date:  2010-09-30       Impact factor: 6.166

2.  DNA hypomethylation affects cancer-related biological functions and genes relevant in neuroblastoma pathogenesis.

Authors:  Gemma Mayol; José I Martín-Subero; José Ríos; Ana Queiros; Marta Kulis; Mariona Suñol; Manel Esteller; Soledad Gómez; Idoia Garcia; Carmen de Torres; Eva Rodríguez; Patricia Galván; Jaume Mora; Cinzia Lavarino
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

3.  CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.

Authors:  Ali Rihani; Bram De Wilde; Fjoralba Zeka; Geneviève Laureys; Nadine Francotte; Gian Paolo Tonini; Simona Coco; Rogier Versteeg; Rosa Noguera; Johannes H Schulte; Angelika Eggert; Raymond L Stallings; Frank Speleman; Jo Vandesompele; Tom Van Maerken
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

4.  Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Authors:  Anneleen Decock; Maté Ongenaert; Jasmien Hoebeeck; Katleen De Preter; Gert Van Peer; Wim Van Criekinge; Ruth Ladenstein; Johannes H Schulte; Rosa Noguera; Raymond L Stallings; An Van Damme; Geneviève Laureys; Joëlle Vermeulen; Tom Van Maerken; Frank Speleman; Jo Vandesompele
Journal:  Genome Biol       Date:  2012-10-03       Impact factor: 13.583

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.